

1 / 50

18

Name of Journal: *World Journal of Gastrointestinal Oncology***Manuscript NO:** 55488**Manuscript Type:** REVIEW

Molecular determinants of response to 5-fluorouracil-based chemotherapy in colorectal cancer: The undisputable role of micro-ribonucleic acids

Amirsaeed Sabeti Aghabozorgi, Mostafa Moradi Sarabi, Reza Jafarzadeh-Esfehani, Shabnaz Koochakkhani, Marziyeh Hassanzadeh, Soudabeh Kavousipour, Ebrahim Eftekhari

Abstract

5-Fluorouracil (5-FU)-based chemotherapy is the main pharmacological therapy for advanced colorectal cancer (CRC). Despite, there has been a significant progress

Match Overview

1	Internet 105 words crawled on 23-Nov-2019 www.nature.com	2%
2	Internet 41 words crawled on 21-Jul-2014 fulltext.calis.edu.cn	1%
3	Crossref 26 words Ebrahim Eftekhari, Fakhraddin Naghibalhossaini. "Carcinoma embryonic antigen expression level as a predictive factor for..."	<1%
4	Crossref 21 words Daniel B. Longley "5-Fluorouracil: mechanisms of action and clinical strategies", <i>Nature Reviews Cancer</i> , 05/2003	<1%
5	Internet 20 words crawled on 25-Jul-2018 www.biomeddefine.com	<1%
6	Internet 20 words crawled on 02-Jun-2020 www.oncotarget.com	<1%
7	Internet 18 words fukuoka-u.repo.nii.ac.jp	<1%



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

12,300 Results

Any time ▾

5-fluorouracil and other fluoropyrimidines in colorectal ...

<https://www.sciencedirect.com/science/article/pii/S0163725819301998>

Feb 01, 2020 · 5-Fluorouracil (5-FU) is an essential component of systemic **chemotherapy** for **colorectal cancer** (CRC) in the palliative and adjuvant settings. Over the past four decades, several modulation strategies including the implementation of 5-FU-based combination regimens and 5-FU pro-drugs have been developed and tested to increase the anti-tumor activity of 5-FU and to overcome ...

Cited by: 5

Author: Sona Vodenkova, Sona Vodenkova, Tom...

Publish Year: 2020

A Long Non-Coding RNA snaR Contributes to 5-Fluorouracil ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132306>

Jul 31, 2014 · INTRODUCTION. Drug resistance is considered a multifactorial phenomenon that results from a variety of factors, including individual variations in patients and genetic and/or epigenetic differences in tumors (Raguz and Yague, 2008; Tan et al., 2010). Although **chemotherapy** has been widely used for **cancer** treatment, acquisition of drug resistance is considered a substantial obstacle ...

Cited by: 56

Author: Heejin Lee, Chongtae Kim, Ja-Lok Ku, W...

Publish Year: 2014

A microRNA molecular modeling extension for prediction of ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470004>

Background. With an average of 610,000 deaths per year, CRC has become the second most common cause of **cancer** death on a global scale. Because it is most commonly diagnosed at advanced stages, approximately 50 % of patients diagnosed with CRC will surrender to the disease []. From a **molecular** perspective, CRC is characterized by the accumulation of genetic alterations affecting the cellular ...

Cited by: 8

Author: Jian Li, Jian Li, Ulrich R. Mansmann

Publish Year: 2015

ERCC1 expression in patients with colorectal cancer: a ...

<https://jcmtjournal.com/article/view/1721/1284> ▾

Introduction. The antimetabolite, 5-Fluorouracil (5-FU), was introduced in 1957 by Heidelberger et al. []

and today it is the cornerstone of chemotherapeutic regimens in treatment of **colorectal cancer**